|
1
|
Braga-Basaria M, Dobs AS, Muller DC,
Carducci MA, John M, Egan J and Basaria S: Metabolic syndrome in
men with prostate cancer undergoing long-term androgen-deprivation
therapy. J Clin Oncol. 24:3979–3983. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Perner S, Mosquera JM, Demichelis F, Hofer
MD, Paris PL, Simko J, Collins C, Bismar TA, Chinnaiyan AM, De
Marzo AM and Rubin MA: TMPRSS2-ERG fusion prostate cancer: An early
molecular event associated with invasion. Am J Surg Pathol.
31:882–888. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kolahdoozan S, Sadjadi A, Radmard AR and
Khademi H: Five common cancers in Iran. Arch Iran Med. 13:143–146.
2010.PubMed/NCBI
|
|
4
|
Center MM, Jemal A, Lortet-Tieulent J,
Ward E, Ferlay J, Brawley O and Bray F: International variation in
prostate cancer incidence and mortality rates. Eur Urol.
61:1079–1092. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wong MC, Goggins WB, Wang HH, Fung FD,
Leung C, Wong SY, Ng CF and Sung JJ: Global incidence and mortality
for prostate cancer: Analysis of temporal patterns and trends in 36
countries. Eur Urol. June 8–2016.(Epub ahead of print). View Article : Google Scholar
|
|
6
|
Kallioniemi OP and Visakorpi T: Genetic
basis and clonal evolution of human prostate cancer. Adv Cancer
Res. 68:225–255. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Boyd LK, Mao X and Lu YJ: The complexity
of prostate cancer: Genomic alterations and heterogeneity. Nat Rev
Urol. 9:652–664. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Heidenreich A, Bellmunt J, Bolla M, Joniau
S, Mason M, Matveev V, Mottet N, Schmid HP, van der Kwast T, Wiegel
T, et al: EAU guidelines on prostate cancer. Part 1: Screening,
diagnosis, and treatment of clinically localised disease. Eur Urol.
59:61–71. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Damaschke N, Yang B, Bhusari S, Svaren J
and Jarrard D: Epigenetic susceptibility factors for prostate
cancer with aging. The Prostate. 2013.73(16): 1721–1730. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Parent ME and Siemiatycki J: Occupation
and prostate cancer. Epidemiol Rev. 23:138–143. 2015. View Article : Google Scholar
|
|
11
|
Salmaninejad A, Sadeghi N and Ghadami S:
Alterations of KRAS exon 2 codon 12/13 mutation status in prostatic
adenocarcinoma; Bioinformatics aspects. Arch Can Res. 4:22016.
View Article : Google Scholar
|
|
12
|
Shen MM and Abate-Shen C: Molecular
genetics of prostate cancer: New prospects for old challenges.
Genes Dev. 24:1967–2000. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Eeles RA, Al Olama AA, Benlloch S,
Saunders EJ, Leongamornlert DA, Tymrakiewicz M, Ghoussaini M,
Luccarini C, Dennis J, Jugurnauth-Little S, et al: Identification
of 23 new prostate cancer susceptibility loci using the iCOGS
custom genotyping array. Nat Genet. 45:385–391, 391e1-2. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Takata R, Akamatsu S, Kubo M, Takahashi A,
Hosono N, Kawaguchi T, Tsunoda T, Inazawa J, Kamatani N, Ogawa O,
et al: Genome-wide association study identifies five new
susceptibility loci for prostate cancer in the Japanese population.
Nat Genet. 42:751–754. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Barbieri CE, Demichelis F and Rubin MA:
Molecular genetics of prostate cancer: Emerging appreciation of
genetic complexity. Histopathology. 60:187–198. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tomlins SA, Laxman B, Dhanasekaran SM,
Helgeson BE, Cao X, Morris DS, Menon A, Jing X, Cao Q, Han B, et
al: Distinct classes of chromosomal rearrangements create oncogenic
ETS gene fusions in prostate cancer. Nature. 448:595–599. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kumar-Sinha C, Tomlins SA and Chinnaiyan
AM: Recurrent gene fusions in prostate cancer. Nat Rev Cancer.
8:497–511. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Santarius T, Shipley J, Brewer D, Stratton
MR and Cooper CS: A census of amplified and overexpressed human
cancer genes. Nat Rev Cancer. 10:59–64. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Salmaninejad A, Ghadami S, Dizaji MZ,
Golchehre Z, Estiar MA, Zamani MR, Ebrahimzadeh-Vesal R, Nowroozi
MR and Shakoori A: Molecular characterization of KRAS, BRAF, and
EGFR genes in cases with prostatic adenocarcinoma; reporting
bioinformatics description and recurrent mutations. Clin Lab.
61:749–759. 2015.PubMed/NCBI
|
|
20
|
Brown RS, Edwards J, Dogan A, Payne H,
Harland SJ, Bartlett JM and Masters JR: Amplification of the
androgen receptor gene in bone metastases from hormone-refractory
prostate cancer. J Pathol. 198:237–244. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Saramäki OR, Tammela TL, Martikainen PM,
Vessella RL and Visakorpi T: The gene for polycomb group protein
enhancer of zeste homolog 2 (EZH2) is amplified in late-stage
prostate cancer. Genes Chromosomes Cancer. 45:639–645. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Saramäki O, Willi N, Bratt O, Gasser TC,
Koivisto P, Nupponen NN, Bubendorf L and Visakorpi T: Amplification
of EIF3S3 gene is associated with advanced stage in prostate
cancer. Am J Pathol. 159:2089–2094. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bloch M, Ousingsawat J, Simon R, Schraml
P, Gasser TC, Mihatsch MJ, Kunzelmann K and Bubendorf L: KCNMA1
gene amplification promotes tumor cell proliferation in human
prostate cancer. Oncogene. 26:2525–2534. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ren B, Yu G, Tseng GC, Cieply K, Gavel T,
Nelson J, Michalopoulos G, Yu YP and Luo JH: MCM7 amplification and
overexpression are associated with prostate cancer progression.
Oncogene. 25:1090–1098. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang R, Xu J, Saramäki O, Visakorpi T,
Sutherland WM, Zhou J, Sen B, Lim SD, Mabjeesh N, Amin M, et al:
PrLZ, a novel prostate-specific and androgen-responsive gene of the
TPD52 family, amplified in chromosome 8q21. 1 and overexpressed in
human prostate cancer. Cancer Res. 64:1589–1594. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Saramäki OR, Savinainen KJ, Nupponen NN,
Bratt O and Visakorpi T: Amplification of hypoxia-inducible factor
1alpha gene in prostate cancer. Cancer Genet Cytogenet. 128:31–34.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Rimawi MF, Mayer IA, Forero A, Nanda R,
Goetz MP, Rodriguez AA, Pavlick AC, Wang T, Hilsenbeck SG, et al:
Multicenter phase II study of neoadjuvant lapatinib and trastuzumab
with hormonal therapy and without chemotherapy in patients with
human epidermal growth factor receptor 2–overexpressing breast
cancer: TBCRC 006. J Clin Oncol. 31:1726–1731. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cobleigh MA, Vogel CL, Tripathy D, Robert
NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman
G and Slamon DJ: Multinational study of the efficacy and safety of
humanized anti-HER2 monoclonal antibody in women who have
HER2-overexpressing metastatic breast cancer that has progressed
after chemotherapy for metastatic disease. J Clin Oncol.
17:2639–2648. 1999.PubMed/NCBI
|
|
29
|
Poovassery JS, Kang JC, Kim D, Ober RJ and
Ward ES: Antibody targeting of HER2/HER3 signaling overcomes
heregulin-induced resistance to PI3K inhibition in prostate cancer.
Int J Cancer. 137:267–277. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Rao K, Gaughan L, Robson C and McCracken
S: The role of the HER2 and HER3 in prostate cancer and their
potential as therapeutic targets. Eur J Cancer. 61:S177–S178. 2016.
View Article : Google Scholar
|
|
31
|
Baek KH, Hong ME, Jung YY, Lee CH, Lee TJ,
Park ES, Kim MK, Yoo JH and Lee SW: Correlation of AR, EGFR, and
HER2 expression levels in prostate cancer: Immunohistochemical
analysis and chromogenic in situ hybridization. Cancer Res Treat.
44:50–56. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Reese DM, Small EJ, Magrane G, Waldman FM,
Chew K and Sudilovsky D: HER2 protein expression and gene
amplification in androgen-independent prostate cancer. Am J Clin
Pathol. 116:234–239. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yan M, Schwaederle M, Arguello D, Millis
SZ, Gatalica Z and Kurzrock R: HER2 expression status in diverse
cancers: Review of results from 37,992 patients. Cancer Metastasis
Rev. 34:157–164. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yamanaka Y, Friess H, Kobrin MS, Büchler
M, Kunz J, Beger HG and Korc M: Overexpression of HER2/neu oncogene
in human pancreatic carcinoma. Hum Pathol. 24:1127–1134. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Nuciforo PG, Pellegrini C, Fasani R,
Maggioni M, Coggi G, Parafioriti A and Bosari S: Molecular and
immunohistochemical analysis of HER2/neu oncogene in synovial
sarcoma. Hum Pathol. 34:639–645. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Salmaninejad A, Estiar MA, Gill RK, Shih
JH, Hewitt S, Jeon HS, Fukuoka J, Shilo K, Shakoori A and Jen J:
Expression analysis of p16, c-Myc, and mSin3A in non-small cell
lung cancer by computer aided scoring and analysis (CASA). Clin
Lab. 61:549–559. 2015.PubMed/NCBI
|
|
37
|
Hanna WM, Rüschoff J, Bilous M, Coudry RA,
Dowsett M, Osamura RY, Penault-Llorca F, van de Vijver M and Viale
G: HER2 in situ hybridization in breast cancer: clinical
implications of polysomy 17 and genetic heterogeneity. Mod Pathol.
27:4–18. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Bar-Shira A, Pinthus JH, Rozovsky U,
Goldstein M, Sellers WR, Yaron Y, Eshhar Z and Orr-Urtreger A:
Multiple genes in human 20q13 chromosomal region are involved in an
advanced prostate cancer xenograft. Cancer Res. 62:6803–6807.
2002.PubMed/NCBI
|
|
39
|
Sattler HP, Lensch R, Rohde V, Zimmer E,
Meese E, Bonkhoff H, Retz M, Zwergel T, Bex A, Stoeckle M and
Wullich B: Novel amplification unit at chromosome 3q25-q27 in human
prostate cancer. Prostate. 45:207–215. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Elo JP and Visakorpi T: Molecular genetics
of prostate cancer. Ann Med. 33:130–141. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Edwards J, Mukherjee R, Munro AF, Wells
AC, Almushatat A and Bartlett JM: HER2 and COX2 expression in human
prostate cancer. Eur J Cancer. 40:50–55. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Edwards J, Krishna NS, Witton CJ and
Bartlett JM: Gene amplifications associated with the development of
hormone-resistant prostate cancer. Clin Cancer Res. 9:5271–2581.
2003.PubMed/NCBI
|
|
43
|
Nupponen NN, Kakkola L, Koivisto P and
Visakorpi T: Genetic alterations in hormone-refractory recurrent
prostate carcinomas. Am J Pathol. 153:141–148. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Lass U, Hartmann C, Capper D, Herold-Mende
C, von Deimling A, Meiboom M and Mueller W: Chromogenic in situ
hybridization is a reliable alternative to fluorescence in situ
hybridization for diagnostic testing of 1p and 19q loss in
paraffin-embedded gliomas. Brain Pathol. 23:311–318. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zhang Y, Perez T, Blondin B, Du J, Liu P,
Escarzaga D, et al: Identification of FISH biomarkers to detect
chromosome abnormalities associated with prostate adenocarcinoma in
tumour and field effect environment. BMC Cancer. 14:1292014.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Arnould L, Denoux Y, MacGrogan G,
Penault-Llorca F, Fiche M, Treilleux I, Mathieu MC, Vincent-Salomon
A, Vilain MO and Couturier J: Agreement between chromogenic in situ
hybridisation (CISH) and FISH in the determination of HER2 status
in breast cancer. Br J Cancer. 88:1587–1591. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Brimo F, Montironi R, Egevad L,
Erbersdobler A, Lin DW, Nelson JB, Rubin MA, van der Kwast T, Amin
M and Epstein JI: Contemporary grading for prostate cancer:
Implications for patient care. Eur Urol. 63:892–901. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Heidenreich A, Bastian PJ, Bellmunt J,
Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T,
Zattoni F and Mottet N: European Association of Urology: EAU
guidelines on prostate cancer. Part 1: Screening, diagnosis, and
local treatment with curative intent - update 2013. Eur Urol.
65:124–137. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Tanner M, Gancberg D, Di Leo A, Larsimont
D, Rouas G, Piccart MJ and Isola J: Chromogenic in situ
hybridization: A practical alternative for fluorescence in situ
hybridization to detect HER-2/neu oncogene amplification in
archival breast cancer samples. Am J Pathol. 157:1467–1472. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Lennartz M, Minner S, Brasch S, Wittmann
H, Paterna L, Angermeier K, Öztürk E, Shihada R, Ruge M, Kluth M,
et al: The combination of DNA ploidy status and PTEN/6q15 deletions
provides strong and independent prognostic information in prostate
cancer. Clin Cancer Res. 22:2802–2811. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Di Lorenzo G, Tortora G, D'Armiento FP, De
Rosa G, Staibano S, Autorino R, D'Armiento M, De Laurentiis M, De
Placido S, Catalano G, et al: Expression of epidermal growth factor
receptor correlates with disease relapse and progression to
androgen-independence in human prostate cancer. Clin Cancer Res.
8:3438–3444. 2002.PubMed/NCBI
|
|
52
|
Neto AS, Tobias-Machado M, Wroclawski ML,
Fonseca FL, Teixeira GK, Amarante RD, Wroclawski ER and Del Giglio
A: Her-2/neu expression in prostate adenocarcinoma: A systematic
review and meta-analysis. J Urol. 184:842–850. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Qi M, Yang X, Zhang F, Lin T, Sun X, Li Y,
Yuan H, Ren Y, Zhang J, Qin X and Han B: ERG rearrangement is
associated with prostate cancer-related death in Chinese prostate
cancer patients. PLoS One. 9:e849592014. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Ross JS, Sheehan C, Hayner-Buchan AM,
Ambros RA, Kallakury BV, Kaufman R, Fisher HA and Muraca PJ:
HER-2/neu gene amplification status in prostate cancer by
fluorescence in situ hybridization. Hum Pathol. 28:827–833. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Valtorta E, Misale S, Sartore-Bianchi A,
Nagtegaal ID, Paraf F, Lauricella C, Dimartino V, Hobor S, Jacobs
B, Ercolani C, et al: KRAS gene amplification in colorectal cancer
and impact on response to EGFR-targeted therapy. Int J Cancer.
133:1259–1265. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Park YS, Hwang HS, Park HJ, Ryu M-H, Chang
H-M, Yook JH, Kim BS, Jang SJ and Kang YK: Comprehensive analysis
of HER2 expression and gene amplification in gastric cancers using
immunohistochemistry and in situ hybridization: Which scoring
system should we use? Hum Pathol. 43:413–422. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Jacquemier J, Spyratos F, Esterni B,
Mozziconacci M-J, Antoine M, Arnould L, Lizard S, Bertheau P,
Lehmann-Che J, Fournier CB, et al: SISH/CISH or qPCR as alternative
techniques to FISH for determination of HER2 amplification status
on breast tumors core needle biopsies: A multicenter experience
based on 840 cases. BMC Cancer. 13:3512013. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Horii R, Matsuura M, Iwase T, Ito Y and
Akiyama F: Comparison of dual-color in-situ hybridization and
fluorescence in-situ hybridization in HER2 gene amplification in
breast cancer. Breast Cancer. 21:598–604. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Rosa FE, Santos RM, Rogatto SR and
Domingues MA: Chromogenic in situ hybridization compared with other
approaches to evaluate HER2/neu status in breast carcinomas. Braz J
Med Biol Res. 46:207–216. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Kiyose S, Igarashi H, Nagura K, Kamo T,
Kawane K, Mori H, Ozawa T, Maeda M, Konno K, Hoshino H, et al:
Chromogenic in situ hybridization (CISH) to detect HER2 gene
amplification in breast and gastric cancer: comparison with
immunohistochemistry (IHC) and fluorescence in situ hybridization
(FISH). Pathol Int. 62:728–734. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Liu HL, Gandour-Edwards R, Lara PN Jr, de
Vere White R and LaSalle JM: Detection of low level HER-2/neu gene
amplification in prostate cancer by fluorescence in situ
hybridization. Cancer J. 7:395–403. 2001.PubMed/NCBI
|
|
62
|
Ross JS, Sheehan CE, Hayner-Buchan AM,
Ambros RA, Kallakury BV, Kaufman RP Jr, Fisher HA, Rifkin MD and
Muraca PJ: Prognostic significance of HER-2/neu gene amplification
status by fluorescence in situ hybridization of prostate carcinoma.
Cancer. 79:2162–2170. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Sadasivan R, Morgan R, Jennings S,
Austenfeld M, Van Veldhuizen P, Stephens R and Noble M:
Overexpression of Her-2/neu may be an indicator of poor prognosis
in prostate cancer. J Urol. 150:126–131. 1993.PubMed/NCBI
|
|
64
|
Mark HF, Feldman D, Das S, Kye H, Mark S,
Sun CL and Samy M: Fluorescence in situ hybridization study of
HER-2/neu oncogene amplification in prostate cancer. Exp Mol
Pathol. 66:170–178. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Murphy AJ, Hughes CA, Barrett C, Magee H,
Loftus B, O'Leary JJ and Sheils O: Low-level TOP2A amplification in
prostate cancer is associated with HER2 duplication, androgen
resistance, and decreased survival. Cancer Res. 67:2893–2898. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Savinainen KJ, Saramäki OR, Linja MJ,
Bratt O, Tammela TL, Isola JJ and Visakorpi T: Expression and gene
copy number analysis of ERBB2 oncogene in prostate cancer. Am J
Pathol. 160:339–345. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Loring P, Cummins R, O'Grady A and Kay EW:
HER2 positivity in breast carcinoma: A comparison of chromogenic in
situ hybridization with fluorescence in situ hybridization in
tissue microarrays, with targeted evaluation of intratumoral
heterogeneity by in situ hybridization. Appl Immunohistochem Mol
Morphol. 13:194–200. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
van de Vijver M, Bilous M, Hanna W,
Hofmann M, Kristel P, Penault-Llorca F and Rüschoff J: Chromogenic
in situ hybridisation for the assessment of HER2 status in breast
cancer: An international validation ring study. Breast Cancer Res.
9:R682007. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Elliott K, Hamilton PW and Maxwell P:
Fluorescence (FISH) and chromogenic (CISH) in situ hybridisation in
prostate carcinoma cell lines: Comparison and use of virtual
microscopy. Br J Biomed Sci. 65:167–171. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Penault-Llorca F, Bilous M, Dowsett M,
Hanna W, Osamura RY, Rüschoff J and van de Vijver M: Emerging
technologies for assessing HER2 amplification. Am J Clin Pathol.
132:539–548. 2009. View Article : Google Scholar : PubMed/NCBI
|
